Parcalin 1mg 1 mg

Pays: Jordanie

Langue: anglais

Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Ingrédients actifs:

Rasagiline 1 mg

Disponible depuis:

شركة التقدم للصناعات الدوائية - Al-Taqqadom Pharmaceutical Industries

Code ATC:

N04BD02

DCI (Dénomination commune internationale):

Rasagiline 1 mg

Dosage:

1 mg

Unités en paquet:

28

Fabriqué par:

GENEPHARM S.A/GREECE (اليونان)

Descriptif du produit:

21.47 :سعر الجمهور + الضريبة

Notice patient

READ ALL OF THIS LEAFLET CAREFULLY
BEFORE
YOU START TAKING THIS MEDICINE.
- Keep this leaflet.You may need to read it
again.
- If you have any further questions, ask
your doctor or pharmacist.
- This medicine has been prescribed for
you. Do not pass it on to others. It may
harm them, even if their symptoms are the
same as yours.
- If any of the side effects gets serious, or
if you notice any side effects not listed in
this
leaflet,
please
tell
your
doctor
or
pharmacist.
IN THIS LEAFLET:
1. What PARCALIN is and what it is used
for.
2. Before you take PARCALIN
3. How to take PARCALIN
4. Possible side effects.
5. How to store PARCALIN
6. Further information.
1. WHAT PARCALIN IS AND WHAT IT IS
USED FOR:
PHARMACOTHERAPEUTIC GROUP:
Anti-Parkinson-Drugs, Monoamine
oxidase -B inhibitors, ATC code: N04BD02.
THERAPEUTIC INDICATIONS:
PARCALIN is indicated for the treatment of
idiopathic
Parkinson's
disease
(PD)
as
monotherapy
(without
levodopa)
or
as
adjunct
therapy
(with
levodopa)
in
patients with end of dose fluctuations.
2. BEFORE YOU TAKE PARCALIN:
A. DO NOT TAKE PARCALIN
IN:
- Hypersensitivity to the active substance
or to any of the excipients.
-
Concomitant
treatment
with
other
monoamine
oxidase
(MAO)
inhibitors
(including medicinal and natural products
without prescription e.g. St. John's Wort)
or pethidine. At least 14 days must elapse
between discontinuation of Rasagiline and
initiation of treatment with MAO inhibitors
or pethidine.
-
In
patients
with
severe
hepatic
impairment.
B. TAKE SPECIAL CARE WITH PARCALIN:
- The concomitant use of Rasagiline and
fluoxetine
or
fluvoxamine
should
be
avoided. At least five weeks should elapse
between discontinuation of fluoxetine and
initiation of treatment with Rasagiline. At
least
14
days
should
elapse
between
discontinuation
of
Rasagiline
and
initiation of treatment with fluoxetine or
fluvoxamine.
-
Impulse
control
disorders
(ICDs)
can
occur in patients treated with dopamine
agonists and/or dopaminergic
treatments.
Similar reports of ICDs have also been
received post-market